Evidence map›Paper›PMID 41644274›Full record

ArticleBasic & clinical pharmacology & toxicology2026

Association Between Levels of the Acute Phase Proteins Alpha-1-Acid Glycoprotein and C-Reactive Protein and Serum Concentrations of Clozapine: A Study of 1106 Therapeutic Drug Monitoring Samples.

Ketil Arne Espnes, Olav Spigset, Guro Emilie Bratt, Marit Tilrem, Sarita Hamnes, Eirik Skogvoll, Ragnhild Bergene Skråstad

Abstract read
In one paragraph

Article in Basic & clinical pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ketil Arne EspnesDepartment of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.ORCID https://orcid.org/0000-0002-3566-3328
Olav SpigsetDepartment of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.ORCID https://orcid.org/0000-0001-7902-9014
Guro Emilie BrattDepartment of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Marit TilremDepartment of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Sarita HamnesDepartment of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Eirik SkogvollClinic of Anaesthesia and Intensive Care, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.ORCID https://orcid.org/0000-0002-6984-0708
Ragnhild Bergene SkråstadDepartment of Clinical Pharmacology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.ORCID https://orcid.org/0000-0003-3810-0413

Funding

Clinic of Laboratory Medicine, St. Olav's Hospital P-101201-20
6 · The paper itself

Abstract

Several publications have reported elevated clozapine concentrations in patients experiencing infections or inflammatory reactions. Proposed mechanisms include increased levels of pro-inflammatory cytokines that may inhibit clozapine metabolism and enhanced binding of clozapine to the acute phase protein alpha-1-acid glycoprotein (AGP). We collected serum samples sent to our routine laboratory over a 15-month period for the analysis of clozapine. In the 1106 eligible samples, we measured AGP and C-reactive protein (CRP) levels. By using a linear mixed effects regression model, we found a clear association between higher AGP and CRP levels and higher dose-adjusted clozapine concentrations. As an example, an increase in the CRP level from 5 to 60 mg/L or an increase in the AGP level from 0.5 to 1.5 g/L would be expected to cause a more than twofold increase in the clozapine concentration. Our findings support and extend previous case reports and studies, suggesting that increased AGP levels during inflammatory states may play a significant role in the rise of clozapine plasma concentrations observed during illness. We propose that in addition to the clozapine concentration, CRP levels and clinical signs of adverse effects and toxicity should be closely monitored in patients with infectious or inflammatory diseases.

Indexed as

Antipsychotic AgentsClozapineC-Reactive ProteinDrug MonitoringOrosomucoidBiomarkersDose-Response Relationship, DrugFemaleHumansInflammationMaleAntipsychotic AgentsBiomarkersClozapineC-Reactive ProteinOrosomucoidalpha‐1‐acid glycoproteinclozapineC‐reactive proteininflammationtherapeutic drug monitoring

Identifiers

PMID41644274
PMCPMC12875762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.